Member Info for Retireby40

Erm AVCT owns the IP and as much as ODX is a great comit will manufacture the tests when ready and will get a small slice of a small margin test. Still it’s great it’s now on many a radar but these ludicrous share price projections are just that.

The fact two large IIs sold out makes me a little nervous too. I’ve known the company for many years and unlike many a Johnny come lately and maybe we’ll invest and will see what next week brings share price wise.

You’ve got a point re spreading risk, can’t argue with that.

I will say that the MWG revenue-sharing deal wasn’t not included in the £2m Q1 orders and although the deal will make a decent contribution there’s a lot more to SKIN.

Some decent notes by a holder -

https://twitter.com/eddiemorranzt/status/1251059127020896256?s=21

But they kit is going to compete with Roche and PrimerDesign which are leading the way. That said I’ve no doubt the demand outstrips supply to not an issue. Surely the interesting one is the second test but they hadn’t started developing it end of March and it’s a more complex test. They tells me AVCT will launch its kit first and given that can be self-administered (like a pregnancy test) unlike GDR’s I think it might be too little too late.
I’m sure the first test will do well though but PrimerDesign will launch its new test in May.

From LSE NCYT
Brilliant post.
Focus should now switch to the "direct-to-PCR" extraction method
Fri 21:45
It's time for any serious investors to stop focusing (almost obsessing) on sales updates and read the last RNS again.
It is clear to me that the company is now being driven by manufacturing, not updating the market with every EUA, £1m+ order we receive. I think we can be safe in the knowledge that we are selling everything we make based on the fact we are looking to DOUBLE the number of tests from 4 to 8m whilst continuing to look for other third party manufacturers to yet further increase...!
Instead, I'd personally look to focus on the "direct-to-PCR" extraction method and the significance of this to the future of COVID19 testing, testing in the UK.
The first we heard of this new extraction methodology was in the previous RNS. Why is it important?
1. This removes the need for some scarce reagents
2. Significantly reduces the number of extraction steps
3. Allows for faster cycle times, higher throughputs and cost savings
What does Graham and the directors think of it?
"The Directors believe this innovation should facilitate an INCREASE IN TESTING CAPACITY for COVID-19, removing a current bottleneck in sample processing for laboratories."
Reading the above extract, I wouldn't be surprised if it includes GSK & AstraZeneca involvement to generate the national interest and help us scale up.
I also expect this to therefore be Government endorsed and expect a big push in the weeks ahead from the media and Matt Han**** etc, especially off the back of the recent news from the WHO that casts doubt over the reliability of AB tests.
Picture the first week of May, selling 8m tests per month and just about to launch a new extraction method for PCR testing with backing of key players and Government...

*The forecast of 4 times FY19 seemed optimistic but £2m in orders has been achieved in Q1.

I didn’t mention the numerous multiyear contrasts with several top 20 cosmetic cos which is recurring revenue and should be on the rise. I think the market is waking up and I can see this moving higher in the coming weeks. A good time to invest.

To be fair with SKIN it’s about going through the RNSs and I believe the investment case speaks for itself. The turnaround since the current BoD came in has been something else. The business model transformation and the acquisition of Rinocloud has made this a no-brainier for me.

The forecast of 4 times FY19 seemed optimistic but £4m in orders has been achieved in Q1. I doubt Q2 won’t be as impressive but given the cash in bank from the last raise, investing in increasing lab capacity they should be cash flow break even and then positive soon.

The revenue sharing deal with MWG is great and no doubt those orders will continue to rise. I’m sure once China is fully reopened SKIN will be integral in their move away from animal testing as the MOU testifies. A lot going on and if they hit £4m FY20 and are generating cash it should be nearer 10p than 1p IMO.

Very good point indeed Piper. That’s a massive factor against Roche. We’ll get a wriggle on then ODX et al!

I’m sure the UK Gov is keen to use a UK made test and especially from a collaboration it out together but they’ll go with whatever is reliable and launched first.

ODX is a great little company and CD4 is remarkable albeit it’s taken years and years to get it stable and to the market so it will be fine regardless but Roche is a major player and will get its test rolled out quickly.

The pharmaceutical giant Roche has devised a new coronavirus antibody test, which it is aiming to launch in the UK next month.

https://www.theguardian.com/world/2020/apr/17/roche-coronavirus-antibody-test-uk

Apologies for a pump.

A low market cap PLCs with great potential then check out MWG. Current market cap £6m with £20m spent on its tech and cash snd current orders worth half its market cap.

Regardless of covid their tech is amazing snd protected. Given the issues with clean water which is only going to become more of an issue these guys are going to be massive. Sadly for early investors it’s taken a lot of money, sweat and tears but now they’ll start to bear the fruits of their labour with a more commercially minded BoD. A snip given cash in the bank, backdated orders to fulfil, increased production capacity with SKIN bearing the costs it’s a great time to buy and added with the AI which is a bolt-in to existing clients

They’ll always be room for others and we’ll wanna develop our own but I hope they get a wriggle on before Roche corners the market.

Roche Holding AG said Friday that it is developing a new serology test to detect antibodies in patients who have been exposed to the new coronavirus.
The Swiss drug maker said the Elecsys Anti-Sars-CoV-2 immunoassay is an in-vitro test to detect antibodies and assess the body's immune reaction to Sars-CoV-2, better known as Covid-19, using human serum and plasma from a blood sample.
Roche said the test would be available by early May for countries under the European Union's CE mark, and that it is working with the U.S. Food and Drug Administration for an emergency use authorization.
The company said it is planning to ramp-up monthly production to reach high double-digit million tests by June.
"The antibody test is an important next step in the fight against Covid-19. Roche's antibody test can be quickly scaled and made broadly available around the world as our instrument infrastructure is already in place," said Thomas Schinecker, Chief Executive for Roche Diagnostics.

I’m surprised the co hasn’t made a statement or would there be considered premature.

Just FYI Sky News at 13:30 will be worth a watch for the sector at large.

For even a small amount. The MMs take the biscuit on this. Make a bloody market.

Genedrive is releasing 2 tests, the first as announced end of March they’d started development and it should be ready end of May and that requires equipment much like NCYT’s. NCYt is selling out, is only one of two tests with WHO validation. They’re also making a faster test with no reagents for May which ties in with Uninof Cambridge, AZN and is doing 30,000 tests a day so 1m a month.

For me and many others I imagine the second test GDR is the most interesting but how long will this take to be released as I assume they haven’t started (read the RNS) and this will take longer than the first. If this is released after AVCT they’ll lose market share given the simplicity of that product and the user can use on their own at home unlike GDR’s which needs administering. Plus AVCT has a multi billion pound partner which GDR doesn’t. That said if this carries on and a second wave comes demand will be there but if there’s a cheaper and simpler alternative that can be mass produced it might be too late.

From the ENS

A second test will also be developed by the Company where it will adapt its formulations to run on the Genedrive(R) instrument platform to provide a rapid point-of-care SARS-COV-2 test to allow testing outside of the main hospital environment in places such as clinics, intensive care units, or where rapid and accurate testing for SARS-COV-2 might be required. The rationale for the two-stage development is that the testing, logistics, validation, and trial work to provide testing on a turnkey instrument system like Genedrive(R) takes additional time compared to an agnostic assay format.

So you’ve got the first test that was already in development at the end of March which should be ready to start producing end of May (8 weeks).
For me and many others I imagine the second test is the most interesting but how long will this take as I assume they haven’t started and this will take longer than the first. If this is released after AVCT they’ll lose market share given the simplicity of that product and the user can use on their own at home unlike GDR’s. That said if this carries on and a second wave comes demand will be there but if there’s a cheaper and simpler alternative that can be mass produced it might be too late.
A second test will also be developed by the Company where it will adapt its formulations to run on the Genedrive(R) instrument platform to provide a rapid point-of-care SARS-COV-2 test to allow testing outside of the main hospital environment in places such as clinics, intensive care units, or where rapid and accurate testing for SARS-COV-2 might be required. The rationale for the two-stage development is that the testing, logistics, validation, and trial work to provide testing on a turnkey instrument system like Genedrive(R) takes additional time compared to an agnostic assay format.

So May is circa 5m tests/month but what’s US OEM producing?
Also, come May a test developed without reagents, faster cycle times, increased throughputs & less costly. Wow. Always progressing/improving. So 60-90 mins, 96 tests becomes fewer mins & more tests without reagents. Hopefully 180 tests in 60 mins or less so 3 results a minute. Complete guess that!

Money munch on advfnToday 13:53
Dr Meng continued: “Our findings show that timed administration of the antioxidant compound sulforaphane, effectively attenuates the severity of the lung fibrosis in this mouse model.”

hTtps://www.manchester.ac.uk/discover/news/new-research-links-body-clocks-to-chronic-lung-diseases/

Apologies wrong boars

Dr Meng continued: “Our findings show that timed administration of the antioxidant compound sulforaphane, effectively attenuates the severity of the lung fibrosis in this mouse model.”

hTtps://www.manchester.ac.uk/discover/news/new-research-links-body-clocks-to-chronic-lung-diseases/

Downing Street has insisted it remains on target to ensure 100,000 tests a day for coronavirus by the end of the month – despite the latest figures showing only a fifth of this number are being carried out.
At the daily briefing for lobby journalists, the prime minister’s spokesman disclosed the statistics while defending the decision to allow Michael Gove’s daughter to be tested for the illness – at a time when some NHS and care home staff are still waiting to be tested themselves.
The test came back negative, meaning that Gove was no longer obliged to self-isolate at home with the rest of his family. The fact that Gove was no longer self-isolating emerged when he was seen jogging in a park near his London home.
On 25 March, at the last prime minister’s questions before the Easter recess , Boris Johnson told MPs that the government was “massively increasing” testing up to 25,000 per day. Later that day he told a press conference that “hopefully very soon” he wanted to reach a target of 250,000 tests a day, although when Matt Han****, the health secretary, set a formal target to be achieved by the end of April, he settled on 100,000 tests a day.
At the Monday briefing, the PM’s spokesman said that in the 24-hour period up to 9am on Sunday, 18,000 tests were carried out in Great Britain.
He said that 2,630 of those tests involved NHS staff being tested at drive-through sites, and that a total of 42,812 NHS staff and their family members had now been tested.
That marked “significant progress on where we were a little over a week ago”, the spokesman claimed.
When it was put to him that the government was still a long way off the 100,000-a-day target set by Han****, the spokesman said he did not accept that. “New capacity is coming on stream all the time,” he said, stressing that there were now 23 drive-through centres open where NHS staff could get tested.